Should I Buy RZLT? RZLT 2026 Analysis

Should You Buy Rezolute Inc (RZLT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.250

1 Day change

-3.85%

52 Week Range

11.460

Analysis Updated At

2026/01/26

Rezolute Inc (RZLT) is not a good buy for a beginner investor with a long-term strategy at this time. The stock has faced significant challenges, including poor clinical trial results, negative sentiment from analysts, and ongoing legal investigations. Technical indicators suggest the stock is overbought, and there are no strong proprietary trading signals or positive catalysts to support a buy decision. It is recommended to hold off on investing in this stock until there is more clarity on its future prospects.

Technical Analysis

The MACD histogram is positive at 0.349, indicating bullish momentum. However, the RSI is at 81.571, signaling an overbought condition. Moving averages are converging, and the stock is trading near its R1 resistance level of 3.454. The pre-market price of $3.48 reflects a -1.99% decline, suggesting potential weakness.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

NULL identified. The stock has no recent positive news or significant trading signals.

Neutral/Negative Catalysts

Disappointing Phase 3 clinical trial results for ersodetug in congenital hyperinsulinism.
Multiple analysts have downgraded the stock and significantly lowered price targets.
Legal investigations into potential securities fraud following the stock's 87.2% drop.
Negative sentiment from hedge funds and insiders.

Financial Performance

In Q1 2026, revenue remained at $0 with no growth. Net income improved slightly to -$18.15M, up 18.03% YoY, but EPS dropped to -$0.18, down 18.18% YoY. The company's financials remain weak with no clear growth trajectory.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have downgraded the stock significantly, with price targets reduced from as high as $20 to as low as $1. While some analysts maintain a Buy rating, the consensus reflects uncertainty about the company's future prospects due to clinical trial failures and reduced growth expectations.

9 Analyst Rating

Wall Street analysts forecast RZLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RZLT is 6.29 USD with a low forecast of 2 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

4 Hold

0 Sell

Moderate Buy

Current: 3.380

Low

Averages

6.29

High

Current: 3.380

Low

Averages

6.29

High

Wedbush

Neutral

maintain

$1 -> $2

AI Analysis

2026-01-08

Reason

Wedbush

Price Target

$1 -> $2

AI Analysis

2026-01-08

maintain

Neutral

Reason

Wedbush raised the firm's price target on Rezolute to $2 from $1 and keeps a Neutral rating on the shares. The firm notes the company reported PK/PD data and detailed glycemic control outcomes from the Phase 3 sunRIZE study of ersodetug in congenital hyperinsulinism. Wedbush believes that the new data demonstrates ersodetug's activity in modulating insulin receptors to reduce both events and time in hypoglycemia in treated patients, although whether the magnitude of benefit is sufficient to support an FDA approval remains unclear.

Guggenheim

Buy

downgrade

$15 -> $6

2025-12-12

Reason

Guggenheim

Price Target

$15 -> $6

2025-12-12

downgrade

Buy

Reason

Guggenheim lowered the firm's price target on Rezolute to $6 from $15 and keeps a Buy rating on the shares. Following the failure of the sunRIZE trial, the firm is eliminating cHI from its model despite managment's "optimism" on a potential path forward, the analyst tells investors. The firm's lower target reflects the elimination of cHI, a lower price point forecast for tHI and lower odds of success, until proven otherwise, for tHI, the analyst noted.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RZLT

Unlock Now

RZLT Should I Buy

RZLT Should I Buy

Should You Buy Rezolute Inc (RZLT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch